1 Min Read
Oct 11 (Reuters) - Exicure Inc:
* Press release - Exicure announces positive phase 1 data for topical anti-TNF compound AST-005 in patients with mild to moderate Psoriasis Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.